featured
Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J. Clin. Oncol 2018 Oct 22;[EPub Ahead of Print], A Hauschild, R Dummer, D Schadendorf, M Santinami, V Atkinson, M Mandalà, V Chiarion-Sileni, J Larkin, M Nyakas, C Dutriaux, A Haydon, C Robert, L Mortier, J Schachter, T Lesimple, R Plummer, K Dasgupta, T Haas, M Shilkrut, E Gasal, R Kefford, JM Kirkwood, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.